2nd Strategic Partnerships for Drug Repurposing Forum

Discover the Latest Indications for Repurposing, Rescuing and Repositioning Existing Drugs to Explore New Innovations

October 26-27, 2017 / Hyatt Regency Boston Harbor / Boston, MA

Led by Our Expert Speaking Faculty, Including:

Craig Wegner,
Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, AstraZeneca Pharmaceuticals

Bruce Bloom,
President and Chief Science Officer, CURES WITHIN REACH

Zhichao Liu,
Staff Fellow, NCTR, FDA

Charles Hong,
Associate Professor, Medicine-Cardiovascular Pharmacology, and Cell and Developmental Biology, Vanderbilt University

Brian Fisher,
Vice President of Operations and Corporate Partnerships, Sturge-Weber Foundation

Pankaj Agarwal,
Senior Fellow, Computational Biology, Glaxosmithkline

Stephen Wong,
Chairman and Professor, Department of Systems Medicine and Bioengineering, and Chief Research Informatics Officer, Houston Methodist

Raymond K. Houck,
President and Chief Executive Officer, Thar Pharmaceuticals

Alex Aliper,
President of European Operations, Insilico Medicine

Aris Persidis,
President, Biovista

Bobbie Austin,
Program Officer, Drug Development Partnership Programs, National Center for Advancing Translational Sciences, NIH

Neal Farber,
Chief Executive Officer and Director, Neurohealing Pharmaceuticals

PROGRAM HIGHLIGHTS

- Identify new technologies used for the evaluation of repurposed drugs
- Engage in case studies and panel discussions on how to excel in searching for drug repurposing opportunities and uncover new indications for existing drugs
- Gain a better understanding of how repurposed drugs can benefit your organization
- Identify new indications of marketed drugs for rare and neglected diseases
- Cover new methods in the pipeline by using innovative strategies to discover new therapeutic uses for existing molecules
- Network and learn from more than 75 of your industry peers
Dear Colleague,

In today's society, life science organizations not only develop strategies and methods to help find cures for diseases; they also utilize data from past clinical trials to uncover potential new indications to repurpose, reposition or rescue a drug. Organizations can use these strategies to expand treatment options for patients by finding ways to repurpose existing drugs. With more than 7,000 known diseases worldwide, drug repurposing provides an alternative route for companies to provide treatments to patients faster.

At ExL's 2nd Strategic Partnership for Drug Repurposing Forum, we will expand on last year's meeting by cover new topics, case studies, and various panel discussions. We will continue to have speakers from all stakeholders in the room, which include life science companies, patient advocacy groups, nonprofits/foundations, and governmental/funding partners. Come network with stakeholders and hear the latest indications for repurposing, rescuing and repositioning existing drugs to explore the newest innovations.

By attending this conference, you will experience 15+ sessions, panels and case studies, including:

- The pathway of bioinformatics for repurposing neglected diseases
- FDA incentives for drug repurposing orphan diseases
- New technologies used for the evaluation of drugs
- The emergence of Big Data
- Drug repurposing successes and challenges
- Academic discoveries and collaborations
- Commercialization funding models in pharmaceutical and biotech companies

VENUE INFORMATION

Hyatt Regency Boston Harbor
101 Harborside Dr, Boston, MA 02128

To make reservations, please call 888-421-1442 and request the negotiated rate for ExL’s October Meetings. You may also make reservations online using the following weblink: http://bit.ly/2sf11dm. The group rate is available until October 4, 2017. Please book your room early, as rooms available at this rate are limited.

*ExL Events is not affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. In the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly email us at info@exlevents.com. ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL's reserved guest room block using the details provided.

WHO SHOULD ATTEND
This conference is designed for representatives from pharmaceutical, biotechnology, nonprofit organizations, patient networks/advocacy groups with responsibilities in the following areas:

- Global Commercialization/Strategy
- Drug Repurposing
- Strategic Partnerships/Alliances
- Program and Portfolio Development
- Corporate Strategy
- Market Access
- Data Architecture/Management/Analytics
- Real-World Data/Big Data
- Clinical Operations
- Pharmacology
- Research and Development
- Product Development
- Scientific/Clinical Development
- Regulatory Affairs
- Informatics/Bioinformatics
- Business Development
- Drug Development
- Rare/Orphan Program Management
- Pipeline/Portfolio Management

This program is also of interest to:

- Specialist Repositioning Companies
- CROs/Clinical Development Organizations
- Drug Compound Screening Service Providers
- Product Identification Service Providers
- Chemical Library Companies
- Data Mining/Acquisition/Capture Organizations
8:00 Registration and Continental Breakfast
9:00 Co-Chairpersons’ Opening Remarks
  Bruce Bloom, President and Chief Science Officer, CURES
  WITHIN REACH
  Craig Wegner, Executive Director, Boston Head, Emerging
  Innovations, Scientific Partnering and Alliances, AstraZeneca
  Pharmaceuticals

9:15 Big Data and Drug Repositioning: Made for Each Other
  • Explore new technologies used for data in the industry
  • Discuss Big Data for every aspect of healthcare, and that is
    relevant to the discovery and development of drugs
  • Understand how to make better decisions about which targets
    to pursue which patient subpopulations, all the way to benefit/
    risk decision support at the point of care
  • Examine how repositioning is benefitting from Big Data like
    never before
  • Review examples and case studies, including Biovista’s Project
    Prodigy
  Aris Persidis, President, Biovista

10:00 Clinical Validation Successes Have Now Emerged From Strategic Open Innovation
  Partnerships – Is This Now a Certified Path for Drug Repositioning
  • Uncover novel technologies, partnerships and funding avenues
    of drug repositioning
  • Implement traditional drug discovery and development from
    idea generation through clinical validation
  • Address validation of repositioning ideas for small and large
    molecule compounds
  • Learn drug repositioning collaborations and processes
  Craig Wegner, Executive Director, Boston Head, Emerging
  Innovations, Scientific Partnering and Alliances, AstraZeneca

10:45 Networking Break

11:15 Partnerships With Sponsors, Patient Advocacy, Government and Research of Drug
  Developments
  • Review all the aspects of how partnerships integrate with each
    other
  • Learn the experiences with each partnership and the drug
    repurposing opportunities
  • Discover how to approach the FDA with new drugs and
    understand which drugs make good candidates for repurposing
  • Identify new strategies and technologies used for drug
    repurposing
  Brian Fisher, Vice President of Operations and Corporate
  Partnerships, Sturge-Weber Foundation
  Bobbie Austin, Program Officer, Drug Development Partnership
  Programs, National Center for Advancing
  Translational Sciences, NIH

12:15 BioVU: Drug Development by Leveraging Human Genetics
  • Explain the potential impact of using human genetic data that is
    linked to longitudinal electronic records
  • Outline a DNA database linked to Vanderbilt University, electronic
    health records used for genome-phenotype information
  • Implement how we need increased therapeutic options!
  • Capitalize on accelerating precision drug development and drug
    repurposing
  Charles Hong, Associate Professor, Medicine-Cardiovascular
  Pharmacology, and Cell and Developmental Biology, Vanderbilt
  University

1:00 Networking Lunch

1:15 Recycling the Recycling Model: Building Economic Incentives Into Generic Drug
  Repurposing
  • Identify repurposed therapy developments and off-label use of
    medicines
  • Explore the high cost of medicine, the low number of new
    therapies in development, the rise of bioinformatics and other
    technologies, and government intervention and support
  • Discuss growing interest in drug repurposing and repositioning.
  • Understand how to create additional economic incentives and
    how to use technologies to drive more treatments to more
    patients more quickly through repurposing
  Bruce Bloom, President and Chief Science Officer, CURES
  WITHIN REACH

1:45 Pharma Experiences and Challenges in Evolving New Technologies for Repurposing
  Drugs
  • Walk through experiences with computational methodologies to
    repurpose drugs including genetics and Cmap
  • Practical challenges in advancing hypotheses into successful
    clinical trials
  • Review implications of drug repurposing for target selection
  Pankaj Agarwal, GSK Senior Fellow, Computational Biology, GlaxoSmithKline

2:20 Networking Break

2:35 Phenotypic Screening and Machine Learning: A Powerful Combination for Future Drug
  Discovery and Repurposing
  • Review phenotypic screening (PS) and how it is becoming a mainstay
    approach for drug development and repurposing
  • Discuss the complexity of biological systems, along with a
    growing understanding of the drawbacks of highly reductive
    approaches, contributing to the surge in PS’s popularity
  • Examine an example that deployed machine learning to
    interface phenotypic screening with target-based profiling,
    identified multiple druggable targets, and used the information
    to repurpose a small-molecule compound for CNS injury
  Hassan Al-Alli, Ph.D., Research Assistant Professor, University
  of Miami; Chief Scientific Officer, TruVitech LLC

3:20 Integrative Technology Platform to Speed Up the Process of Drug Repurposing
  • Introduce the DrugX platform used to repurpose drugs and drug
    combinations
  • Present some novel tools and strategies that are integrated
    together to achieve better drug repurposing and discovery
  • Explore specific case studies at Houston Methodist
    implemented in cancer, rare disease, and neurodegeneration
  • Examine the impact and indication of repurposing opportunities
  Stephen Wong, Chairman and Professor, Department of Systems
  Medicine and Bioengineering, and Chief Research Information
  Officer, Houston Methodist Hospital

3:55 End of Main Conference Day One

“Very good range of speakers.”
Principal Scientist, Syros Pharmaceuticals
8:00 Continental Breakfast

8:45 Co-Chairpersons’ Recap of Day One
Bruce Bloom, President and Chief Science Officer, CURES WITHIN REACH
Craig Wegner, Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, ASTRAZENECA PHARMACEUTICALS

9:00 Predict the Safety and Efficacy of Small Molecules Using Deep Learning Techniques
• Learn the principles for applying deep learning to drug discovery and development
• Grasp how bioinformatics facilitates drug repurposing for rare diseases
• Examine the deeply learned predictor of pharmacological properties of drugs across different biological systems and conditions
• Master a based predicator of pharmaceutical properties of drugs using transcriptomic data to recognize pharmacological properties of multiple drugs across different biological systems and conditions
Alex Aliper, President of European Operations, INSILICO MEDICINE

9:45 Drug Repurposing for Rare Diseases at National Center of Toxicological Research
• Understand an FDA perspective about drug safety and affordability that are taken in consideration for the development process
• Study oncology drugs for rare diseases and cystic fibrosis with drug repurposing
• Highlight sources and proposed frameworks for potential therapeutics
• Establish drug repositioning resources and the marketed drugs
Zhichao Liu, Staff Fellow, NCTR, FDA

10:45 Networking Break

11:15 How to Evaluate the Pricing and Value of a Repurposed Drug
• Outline the forces affecting price changing and how drug developers can react appropriately
• Review the components of a good-value dossier and implications for clinical trial strategy, and the intellectual property considerations that can invite or discourage generic competition
• Focus on seeking partnerships or financing that address pricing considerations at earlier stages in development
Antoun Nabhan, Chief Financial Officer, ESTABLISHMENT LABS

12:00 Engaging the Patient Community in Repurposed Drug Trials
• Balance potential breakthroughs of a repurposed drug and the remaining unanswered questions
• Share the importance of research participation to determine safety and efficacy for new indications
• Explore how to develop a recruitment and retention plan in consideration of the drug’s market availability
• Understand a research foundation’s approach to repurposed drug trials in Parkinson’s disease
Bernadette Siddiqi, Research Programs Officer, THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH

12:45 Networking Lunch

1:45 The Development of a New Molecule of an Old Drug in a New Orphan Disease
• Hear a case study of the development and positioning of Thar Pharmaceuticals’ T121 molecule
• Explore a new molecule based upon Zometa repurposed into Complex Regional Pain Syndrome (CRPS)
• Review the regulatory, patent and development strategies behind the repurposing of Zometa and the lessons learned
Raymond K. Houck, President and Chief Executive Officer, THAR PHARMACEUTICALS

2:30 Explore Development Paths and Challenges in Drug Repurposing
• Examine drug mechanisms and the delivery for repositioned drugs
• Establish funding partners for clinical trials
• Highlight some drug repurposing successes and lessons learned
Neal Farber, Chief Executive Officer, NEUROHEALING PHARMACEUTICALS

3:15 Networking Break

3:45 A KnowledgeBase to Aggregate and Prioritize Data on Generic Drug Repurposing for Cancer
• Raise awareness of the large amount of existing pre-clinical and clinical data
• Provide a resource for researchers engaged in drug repurposing
• Identify the most promising repurposing opportunities for clinical trials
• Inform off-label use and learn from individual treatment experiences
Laura Kleiman, Scientific Research Director, cBio Center, DANA-FARBER CANCER INSTITUTE; Executive Director, CURES WITHIN REACH FOR CANCER

4:15 Conference Concludes

“Very nice summary of how different drugs require different approaches to repurpose them.”
-Scientific Development Consultant, SEGUL THERAPEUTICS, LLC

“It was great to have conversations with experts with experience in repurposing.”
-Manager, Business Development and Analytics, OTSUCA
Registration Fees for Attending the 2nd Strategic Partnership for Drug Repurposing Forum

EARLY BIRD PRICING—Register by, September 15, 2017 $1,895
STANDARD PRICING—Register after, September 15, 2017 $2,095
ONSITE PRICING $2,195

Group Discount Program

Save 25% per person when registering four

For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time). This is a savings of 25% per person.

Save 15% per person when registering three

Can only send three? You can still save 15% off every registration.

Offers may not be combined. Early Bird rates do not apply. To find out more about how you can take advantage of these group discounts, contact our offices at (201) 871-0474.

TERMS AND CONDITIONS: By registering for an ExL Events, Inc. (“ExL”) event, you agree to the following set of terms and conditions listed below:

REGISTRATION FEE: The fee includes the conference, all program materials, and designated continental breakfasts, lunches and refreshments.

PAYMENT: Please make checks payable to: “PMA” You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

**Please Note: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague within five business days of any ExL conference.**

CANCELLATION AND REFUND POLICY: If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event:

- Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date.
- Less than four weeks: A voucher to another ExL event valid for 12 months from the voucher issue date.
- Five days or less: A voucher (minus a $395 processing and documentation fee) to another ExL event valid for 12 months from the voucher issue date.

To receive a refund or voucher, please contact our offices at (201) 871-0474.

CREDIT VOUCHERS: Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applicable now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees’ behalf, the credit voucher will no longer be valid.

ExL Events, Inc. does not and is not obligated to provide a credit voucher to registered attendee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event.

SUBSTITUTION CHARGES: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare, hotel or any other expenses incurred by registrants.

ExL Events’ liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date, content, speakers and/or venue.

*The opinions of ExL’s conference speakers do not necessarily reflect those of the companies they represent, nor ExL Events, Inc.

Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL’s designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL’s designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. ExL EVENTS, INC. EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third-party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.
YES! Register me for this conference!

Name: _______________________________________________
Title: ________________________________________________
Company: ____________________________________________
Dept: ________________________________________________
Address: _____________________________________________
City: _________________________________________________
State: ___________________ Zip: _______________________
Email: _______________________________________________
Phone: _______________________________________________
Fax: _________________________________________________

Method of Payment:
☐ Check  ☐ Credit Card

Card Type: ☐ MasterCard ☐ Visa ☐ AMEX
Card Number: _____________________________________________
Exp. Date: ______________________________________________
Name on Card: ___________________________________________
Signature: ______________________________________________

Please contact me:
☐ I'm interested in marketing opportunities at this event
☐ I wish to receive email updates on ExL Pharma’s upcoming events

CONFERENCE CODE: C523